JP2023519140A5 - - Google Patents
Info
- Publication number
- JP2023519140A5 JP2023519140A5 JP2022552336A JP2022552336A JP2023519140A5 JP 2023519140 A5 JP2023519140 A5 JP 2023519140A5 JP 2022552336 A JP2022552336 A JP 2022552336A JP 2022552336 A JP2022552336 A JP 2022552336A JP 2023519140 A5 JP2023519140 A5 JP 2023519140A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2003756.0A GB202003756D0 (en) | 2020-03-16 | 2020-03-16 | Antagonist of PCSK9 |
| GB2003756.0 | 2020-03-16 | ||
| GBGB2010276.0A GB202010276D0 (en) | 2020-07-03 | 2020-07-03 | PCSK9 antagonist |
| GB2010276.0 | 2020-07-03 | ||
| GB2013998.6 | 2020-09-07 | ||
| GBGB2013998.6A GB202013998D0 (en) | 2020-09-07 | 2020-09-07 | Antagonist of pcsk9 |
| GB2020553.0 | 2020-12-23 | ||
| GBGB2020553.0A GB202020553D0 (en) | 2020-12-23 | 2020-12-23 | Antagonist of pcsk9 |
| PCT/EP2021/056540 WO2021185765A1 (en) | 2020-03-16 | 2021-03-15 | Antagonist of pcsk9 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519140A JP2023519140A (ja) | 2023-05-10 |
| JPWO2021185765A5 JPWO2021185765A5 (https=) | 2024-03-15 |
| JP2023519140A5 true JP2023519140A5 (https=) | 2024-03-15 |
Family
ID=75111564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552336A Ceased JP2023519140A (ja) | 2020-03-16 | 2021-03-15 | Ｐｃｓｋ９のアンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230183694A1 (https=) |
| EP (1) | EP4081642A1 (https=) |
| JP (1) | JP2023519140A (https=) |
| CN (1) | CN115066498A (https=) |
| CA (1) | CA3167849A1 (https=) |
| GB (1) | GB2594788B (https=) |
| WO (1) | WO2021185765A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| GB202020534D0 (en) * | 2020-12-23 | 2021-02-03 | Argonaute Rna Ltd | Conjugate |
| US20250304966A1 (en) * | 2020-12-23 | 2025-10-02 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| WO2023041508A2 (en) * | 2021-09-14 | 2023-03-23 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| GB2618915B (en) * | 2022-05-18 | 2024-08-14 | Argonaute Rna Ltd | Treatment of cardiovascular disease |
| CN117106781B (zh) * | 2023-10-16 | 2024-03-22 | 深圳市茵冠生物科技有限公司 | 修饰的核酸及其产品和应用 |
| CN117210468B (zh) * | 2023-11-06 | 2024-02-20 | 北京悦康科创医药科技股份有限公司 | 靶向调控PCSK9基因表达的siRNA及其应用 |
| CN117384907B (zh) * | 2023-12-11 | 2024-03-29 | 上海鼎新基因科技有限公司 | 抑制PCSK9表达的siRNA分子及其应用 |
| WO2025252223A1 (zh) * | 2024-06-07 | 2025-12-11 | 迈威(上海)生物科技股份有限公司 | 一种抑制PCSK9基因表达的RNAi制剂及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004261002A (ja) * | 2003-01-08 | 2004-09-24 | Tsutomu Suzuki | ｓｉＲＮＡの製造方法 |
| US8067572B2 (en) | 2005-05-25 | 2011-11-29 | The University Of York | Hybrid interfering RNA |
| ES2874149T3 (es) * | 2006-05-11 | 2021-11-04 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
| CN200950065Y (zh) | 2006-05-24 | 2007-09-19 | 王锦峰 | 一种半自动夹板装置 |
| AU2007275365A1 (en) | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| MX2010008394A (es) | 2008-01-31 | 2010-11-12 | Alnylam Pharmaceuticals Inc | Metodos optimizados para administracion de arndc focalizando el gen pcsk9. |
| WO2009114475A2 (en) * | 2008-03-09 | 2009-09-17 | Intradigm Corporation | Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use |
| US9493774B2 (en) * | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| NZ597504A (en) * | 2009-06-15 | 2013-10-25 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene |
| WO2011028938A1 (en) * | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
| EP3358014B1 (en) * | 2010-04-19 | 2020-12-23 | TAGCyx Biotechnologies Inc. | Method for stabilizing functional nucleic acids |
| WO2012058693A2 (en) | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
| ES2770667T3 (es) * | 2013-06-27 | 2020-07-02 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados que se dirigen a PCSK9 |
| CN118697894A (zh) | 2015-08-25 | 2024-09-27 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
| LT3529360T (lt) | 2016-10-18 | 2024-07-25 | Novartis Ag | Metodai, skirti širdies ir kraujagyslių ligų prevencijai mažinant proproteinų konvertazės subtilizino keksino 9 (pcsk9) baltymo kiekį |
| CN109957565B (zh) * | 2017-12-26 | 2023-04-07 | 广州市锐博生物科技有限公司 | 一种修饰的siRNA分子及其应用 |
| US20230139322A1 (en) * | 2017-12-26 | 2023-05-04 | Guangzhou Ribobio Co., Ltd. | SiRNA molecule inhibiting the expression of the PCSK9 gene and use thereof |
| CN117210468B (zh) * | 2023-11-06 | 2024-02-20 | 北京悦康科创医药科技股份有限公司 | 靶向调控PCSK9基因表达的siRNA及其应用 |
-
2021
- 2021-03-15 US US17/908,225 patent/US20230183694A1/en not_active Abandoned
- 2021-03-15 WO PCT/EP2021/056540 patent/WO2021185765A1/en not_active Ceased
- 2021-03-15 EP EP21712703.4A patent/EP4081642A1/en not_active Withdrawn
- 2021-03-15 JP JP2022552336A patent/JP2023519140A/ja not_active Ceased
- 2021-03-15 CN CN202180013447.0A patent/CN115066498A/zh active Pending
- 2021-03-15 CA CA3167849A patent/CA3167849A1/en active Pending
- 2021-03-16 GB GB2103594.4A patent/GB2594788B/en active Active